Literature DB >> 8497125

Immunocytochemical localization of basic fibroblast growth factor in carcinomas and inflammatory lesions of the human digestive tract.

H Ohtani1, S Nakamura, Y Watanabe, T Mizoi, T Saku, H Nagura.   

Abstract

BACKGROUND: Basic fibroblast growth factor (bFGF) is one of the important angiogenic peptides. Clarification of its localization in human cancer and inflammatory diseases is important for the study of angiogenesis. EXPERIMENTAL
DESIGN: Sliced human gastrointestinal carcinomas and inflammatory lesions were frozen after fixation. Immunocytochemical localization of bFGF was studied at the light and electron microscopic levels.
RESULTS: In gastric carcinoma of the diffuse type, bFGF was mainly observed in some of the endothelial cells of the microvasculature and in fibroblasts. Gastric carcinoma of the intestinal type and colonic carcinoma showed the immunoreactivity in fibroblasts, vascular endothelial cells, and in the extracellular matrix (ECM). Carcinoma cells were occasionally positive. In inflammatory lesions, bFGF was most prominent in the ECM. Areas of deposition of bFGF in the ECM partly corresponded to areas of increased immunoreactivity for heparan sulphate proteoglycan. Immunoelectron microscopically, bFGF was localized in the cytosol of fibroblasts and cancer cells but no localization was observed in the lumen of rough endoplasmic reticulum or perinuclear space in any of the cells observed. bFGF was also localized along the luminal surface of vascular endothelial cells, in nuclei of fibroblasts, vascular endothelial cells, smooth muscle cells, and some cancer cells, and in the ECM.
CONCLUSIONS: Extensive localization of bFGF in the ECM was related to the areas of increased vascular permeability and active angiogenesis. In cancer tissues, the distribution pattern of bFGF supports a paracrine mechanism among mesenchymal cells rather than a direct paracrine mechanism on vascular cells from carcinoma cells. Nuclear localization of bFGF may support its activity as a transcriptional factor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8497125

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  14 in total

1.  Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy.

Authors:  R Day; M Ilyas; P Daszak; I Talbot; A Forbes
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

2.  Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: induction by interleukin-1.

Authors:  M V Cronauer; S Stadlmann; H Klocker; B Abendstein; I E Eder; H Rogatsch; A G Zeimet; C Marth; F A Offner
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 3.  Tumor angiogenesis and molecular target therapy in ovarian carcinomas.

Authors:  Masatsugu Ueda; Yoshito Terai; Koji Kanda; Masanori Kanemura; Mikio Takehara; Hikari Futakuchi; Hiroyuki Yamaguchi; Masayuki Yasuda; Koji Nishiyama; Minoru Ueki
Journal:  Hum Cell       Date:  2005-03       Impact factor: 4.174

Review 4.  The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices.

Authors:  R V Iozzo; I R Cohen; S Grässel; A D Murdoch
Journal:  Biochem J       Date:  1994-09-15       Impact factor: 3.857

5.  Immunohistochemical study of gamma delta T cell receptor-positive cells in the capsular region of hepatocellular carcinoma: possible role in defense against expansion of carcinoma in the liver.

Authors:  K Chin; K Morise; K Kanayama; H Nagura
Journal:  J Gastroenterol       Date:  1995-06       Impact factor: 7.527

6.  Expression of basic fibroblast growth factor in intact and ulcerated human gastric mucosa.

Authors:  M A Hull; J L Brough; D G Powe; G I Carter; D Jenkins; C J Hawkey
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

7.  Expression of fibroblast growth factor-1 and fibroblast growth factor-2 in normal liver and hepatocellular carcinoma.

Authors:  N H Chow; K S Cheng; P W Lin; S H Chan; W C Su; Y N Sun; X Z Lin
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

8.  Impact of fibroblast growth factor-2 on tumor microvascular architecture. A tridimensional morphometric study.

Authors:  M A Konerding; E Fait; C Dimitropoulou; W Malkusch; C Ferri; R Giavazzi; D Coltrini; M Presta
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

9.  Immunohistochemical localization of basic fibroblast growth factor in the healing stage of mouse gastric ulcer.

Authors:  M Yabu; Y Shinomura; T Minami; Y Matsuzawa
Journal:  Histochemistry       Date:  1993-12

10.  Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.

Authors:  Raffaella Giavazzi; Barbara Sennino; Daniela Coltrini; Angela Garofalo; Romina Dossi; Roberto Ronca; Maria Pia Molinari Tosatti; Marco Presta
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.